AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06301685
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. once a day.
Trial: NCT06114836
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole will be the PPI prescribed for 4 weeks.
Trial: NCT06485557
Drug: sintilimab plus platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy
Trial: NCT06485557
Drug: sintilimab plus platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
Trial: NCT06485557
Drug: sintilimab plus platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.
Trial: NCT05616728
Drug: EDP-235
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT06377410
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant with stable COPD who received N-Acetylcysteine for 1 month
Trial: NCT05153304
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
Trial: NCT05132920
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21
Trial: NCT00000443
Drug: ondansetron (Zofran)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000688
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04946006
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
Trial: NCT06655220
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride
Trial: NCT06655220
Drug: BI 1815368
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1815368
Trial: NCT06655441
Drug: 3% trehalose
DrugBank: Trehalose (DB12310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution with 3% trehalose in sterile saline in multi dose preservative free bottles
Trial: NCT05083572
Drug: Colonic lavage with polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
Trial: NCT05083572
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course.
Trial: NCT06140784
Drug: 0.76% Sodium Monofluorophosphate Dentifrice
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Trial: NCT06140784
Drug: 0.454% Stannous Fluoride Dentifrice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Trial: NCT04949477
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the patient will receive intranasal dexmedetomidine at a dose of 1 μg/kg to the patient 45 min. before the procedure.
Trial: NCT04949477
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patient will receive paracetamol orally \[Rx paracetamol 250 mg/ml\] at a dose of 20 mg/kg given to the patient 45 min before the procedure by drinking.
Trial: NCT05533411
Drug: Donanemab
RxNorm normalized name: Donanemab
DrugBank: Donanemab (DB16647)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT06217055
Drug: remimazolam based MAC
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The surgery will be performed under monitored anesthesia care by maintaining spontaneous breathing using remimazolam.
Trial: NCT06217055
Drug: general anesthesia with sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The surgery will be performed under mechanical ventilation with inhalation general anesthesia
Trial: NCT02968953
Drug: Triheptanoin
RxNorm normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).
Trial: NCT05168163
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05168163
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04849455
Drug: 0.2% ropivacaine local anesthetic continuous erector spinae plane block
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)
Trial: NCT04849455
Drug: 0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
Trial: NCT04849455
Drug: Spinal Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200-300 mcg of spinal morphine
Trial: NCT00004979
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00004979
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06306040
Drug: Nalbuphine Versus Magnesium Sulfate
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions.
Trial: NCT04985435
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 200 mg tablet once daily or 100 mg once daily
Trial: NCT00512811
Drug: furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05755997
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year
Trial: NCT05497804
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05497804
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV/PO
Trial: NCT05497804
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05191680
Drug: Apalutamide Oral Tablet [Erleada]
RxNorm normalized name: apalutamide Oral Tablet [Erleada]
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.
Trial: NCT06439368
Drug: Dezocine
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the end of the operation, dezocine 1.0 mg/kg + sufentanil 2.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was administered immediately after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.
Trial: NCT05051007
Drug: Lidocaine IV
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
Trial: NCT04857138
Drug: RO7300490
RxNorm normalized name: RO7300490
DrugBank: RO7300490 (DB17535)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RO7300490, as described in the Arm Descriptions.
Trial: NCT04857138
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Atezolizumab, as described in the Arm Descriptions.
Trial: NCT05438550
Drug: 14-day high-dose Tegoprazan Dual Therapy (HDDT)
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
Trial: NCT06335927
Drug: HAIC-GEMOX+Cadonilimab+Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
Trial: NCT06405243
Drug: Chromium
RxNorm normalized name: Chromium
DrugBank: Chromium (DB11136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation
Trial: NCT06405243
Drug: l-arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO
Trial: NCT06405243
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selective aromatase inhibitor
Trial: NCT05726136
Drug: acetated Ringers
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
Trial: NCT05345249
Drug: Ropivacaine Hydrochloride Injection
RxNorm normalized name: Ropivacaine Hydrochloride Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigating the effectiveness of erector spinae plane block with ropivacaine for lumbar spinal fusion surgery versus placebo.
Trial: NCT05345249
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT06626620
Drug: Magnesium Sulphate infusion
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes
Trial: NCT06626620
Drug: Terbutaline Infusion
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours
Trial: NCT04511039
Drug: Talazoparib Tosylate
RxNorm normalized name: TALAZOPARIB TOSYLATE
DrugBank: Talazoparib (DB11760)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT05935293
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv administration dexmedetomidine
Trial: NCT05726136
Drug: albumin 5%
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
Trial: NCT00000653
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05701384
Drug: Lazertinib
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160mg po qd
Trial: NCT05588908
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg subcutaneous (s.c) once
Trial: NCT05588908
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg subcutaneous (s.c) once
Trial: NCT05588908
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg subcutaneous (s.c) once
Trial: NCT05588908
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: one s.c. injection of SSGJ-613 once, on Day 1.
Trial: NCT05588908
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)
RxNorm normalized name: Human il-12 (recombinant)
DrugBank: Edodekin alfa (DB15631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one s.c. injection of SSGJ-613 once, on Day 1.
Trial: NCT05588908
Drug: Compound Betamethasone Injection (phase II)
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mL i.m. once on Day 1
Trial: NCT05789017
Drug: Prednisone and Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months.
Trial: NCT05789017
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.
Trial: NCT05789017
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are treated with leflunomide (20 mg/day) during remission maintenance period for 12 months.
Trial: NCT00000733
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06505668
Drug: Atenolol 25 mg
RxNorm normalized name: atenolol 25 MG
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be receiving Atenolol 25mg OD for 2 months.
Trial: NCT06505668
Drug: Ivabradine 10mg
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be receiving Ivabradine 5mg BD for 2 months.
Trial: NCT00002098
Drug: Lentinan
RxNorm normalized name: lentinan
DrugBank: Lentinan (DB13480)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002098
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05075122
Drug: Sargramostim for Injection
RxNorm normalized name: Sargramostim for Injection
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
Trial: NCT05075122
Drug: Pembrolizumab injection
RxNorm normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
Trial: NCT06558032
Drug: Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet of the test drug was given orally under fasting condition
Trial: NCT06087757
Drug: Open Label Clemastine with a blinded randomize withdrawal
RxNorm normalized name: jojoba oil, randomized
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.
Trial: NCT05168527
Drug: Fruquintinib,Albumin Paclitaxel,Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
Trial: NCT04796857
Drug: PD-1 Antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
Trial: NCT04796857
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase
Trial: NCT00440063
Drug: epoetin beta [NeoRecormon]
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT05900648
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by PO
Trial: NCT05900648
Drug: XmAb20717
RxNorm normalized name: Anti-pd1/ctla4 bispecific antibody xmab20717
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by (IV) vein